SAFC Pharma - Pharmaceutical Technology
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

SAFC Pharma

Pipeline Partner for Complex API and Biologics Development and Manufacturing

3050 Spruce Street,
St. Louis,
63103 Other,
United States of America

3050 Spruce Street,
St. Louis,
63103 Other,
United States of America

SAFC® is recognized worldwide as a trusted leader in providing high-quality specialty chemicals and biologics. The SAFC contract manufacturing services business segment offers to pharmaceutical and biopharmaceutical customers GMP custom key intermediates, APIs and drug products with the rare combination of complex small molecule and biologics expertise, providing comprehensive support of product development and manufacturing programs.

From pre-clinical development to large-scale commercialization, including technologies that are just emerging into the marketplace, SAFC’s complete range of technical knowledge, capabilities and experience delivers effective and efficient manufacturing solutions that speed up the development cycle.

Highly potent API manufacturing (HPAPIs)

With over $75 million invested in purpose-built high-containment facilities over the past few years, SAFC leads the market in highly potent API manufacturing. Our capabilities for this specialized production cover the entire range of pipeline operations, from pre-clinical to commercial scale up to 4,000l batches, with the recent opening of a brand new commercial HPAPI facility in Wisconsin. Using SAFC’s unique expertise in small molecule, biologics and high-containment we can meet our customers’ needs with highly potent bioconjugation, and highly potent fermentation-derived APIs.

Fermentation-derived APIs

Combining its exceptional expertise in small molecule chemistry, biologics and high-potent compound handling, SAFC offers unique large-scale fermentation-based high-potent API contract manufacturing services to help customers bring exciting new drugs to market.

Microbial fermentation is necessary for manufacturing such pharmaceutical and biopharmaceutical actives as small organic molecules, proteins, cell wall components (e.g. lipopolysaccharides, lipid A) and DNAs. Product diversity makes fermentation technology a multi-disciplinary expertise associated with microbiology, organic chemistry, biochemistry and molecular biology. Other levels of complexity are revealed with Biosafety Level 2 Large Scale (BSL2-LS) fermentation utilizing Risk Group 2 (RG2) pathogens, and processing in explosion-proof environments.

Antibody drug conjugation (ADCs or bioconjugates)

SAFC has facilities to support the manufacturing of antibody drug conjugates – a mix of chemistries such as potent / cytotoxic APIs and linkers, and biologics. SAFC’s decades of experience in high-potent and linker technology, along with more recent investments in a variety of biotech processes, make SAFC a strong CMO partner to develop this exciting new area of therapeutics.

Viral vectors and vaccines

SAFC is the market leader in the clinical manufacturing of viral products. Using state-of-the art facilities in California, these products are produced for therapeutic applications such as oncology, heart disease and CNS, in addition to next-generation vaccine candidates.

Solid state chemistry and solid form research studies

We offer solid form research studies through our Pharmorphix® brand for every API we manufacture. Our expert scientific team works to investigate, understand and modify the physical properties of the drug substance to ensure patient benefit, rapid development and protection of intellectual property.

R&D services include polymorph investigation, salt selection, physicochemical property optimization, pre-formulation profiling, co-crystal investigations, classical chiral resolution and crystallization studies.

API process development, technology transfer, pilot plant production and commercial manufacturing

Working closely with customers to keep up-to-date with the latest innovations, SAFC continues to invest in the technologies and processes that will best serve upcoming requirements. With experience gained from over 230 DMFs and nine FDA-validated, cGMP manufacturing centers, our large and small molecule portfolio covers niche technologies and a wide capacity range to fully support API advancement, from process development and optimization to technology transfer, pilot plant production and commercial manufacturing.

Financial stability and life sciences experience

Our customers need a partner with the fiscal strength to be around now and in the future. Losing a supply chain partner due to financial instability could be catastrophic. As part of Sigma-Aldrich Corporation and its 50 years of consecutive growth in the life sciences market, SAFC will continue to be available to support today’s ideas and tomorrow’s commercial products.

Passion for quality

SAFC’s nearly 1,800 employees are dedicated to meeting the exact standards necessary for the development and manufacturing of biopharmaceutical and pharmaceutical products. Facilities and manufacturing processes are designed with specific technologies in mind, such as our SafeBridge-certified high-potent containment facilities or Biosafety Level 2 biomanufacturing sites.

The combination of process development, cGMP manufacturing, strong project management, communication, and an overarching passion for quality leads to successful partnerships between SAFC and its clients to bring new therapies and vaccines to market.

Ash Stevens Riverview Facility

Michigan-based contract pharmaceutical manufacturing company Ash Stevens operates two facilities for API process development and production.

Helsinn New Cytotoxic Plant, Biasca

Switzerland-based pharmaceutical ingredient manufacturer Helsinn expanded its Biasca site in Switzerland with a new cytotoxic API manufacturing facility.

SAFC Announces $6.25 Million Expansion at Lenexa Center of Excellence

SAFC®, a member of the Sigma-Aldrich® Group, today announced a $6.25 million investment program to expand its Lenexa, KS, facility and create a global center of excellence for the seamless upstream and downstream production of dry powder media and reagents. The investment, part of S

SAFC Officially Opens New $30 Million High Potency API Facility in Madison

SAFC, a member of the Sigma-Aldrich® Group (NASDAQ: SIAL), today announced the opening of a $30 million expansion to its Madison manufacturing facility in Verona, Wisconsin. Designed to significantly increase the capacity to produce commercial scale high potency active pharmaceutical ing

Visit SAFC Pharma at Informex 2010

Informex is the premier networking event for the chemical industry in the US. It is designed to showcase the chemistry capabilities of high-value, high-quality businesses, as well as companies that invest in R&D, quality systems, applications development and more. Informex will be h

SAFC Launches Raw Materials Sourcing Service for Medical Diagnostics

SAFC Supply Solutions has launched a new materials sourcing offering, designed to meet the medical diagnostics sector’s demand for raw materials that are compliant with international regulatory standards. Ed Roullard, SAFC Supply Solutions’ VP of sales and marketing, explained that the

SAFC Pharma

3050 Spruce Street


St. Louis



United States of America